Commentary|Articles|July 1, 2025

IJMSC Insights: Francois Bethoux on 10 Years With IJMSC

Author(s)Francois Bethoux, MD, Erin E Gyomber

IJMSC Insights offers a closer look at the latest research and the people behind it from the community of the International Journal of Multiple Sclerosis Care (IJMSC) and the Consortium of Multiple Sclerosis Centers (CMSC).

One of the celebrations at the 2025 annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC) had Francois Bethoux, MD, at its center. 2024 marked a decade of his service as editor in chief of the International Journal of MS Care (IJMSC). At the journal's editorial board meeting, he received a plaque and a round of applause from his colleagues. It proved to be only the first recognition Bethoux would receive as he went on to be recognized as a Giant of Multiple Sclerosis® the next night. To add to the celebrations, the entire IJMSC team also received the Thumbs Up award from the International Organization of Multiple Sclerosis Nurses at the meeting's closing ceremony.

Related to this article

October 21st, 2026

CALLIPER Extension Data Show Sustained Disability Outcomes With Vidofludimus Calcium in Progressive MS

Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.

October 21st, 2026

FDA Grants Fast Track to AV-1959R for Alzheimer Prevention

Fast Track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.

October 21st, 2026

Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis

Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.

October 21st, 2026

Divozilimab Cuts Relapse Risk at 1 Year in Phase 3 AQUARELLE Trial of NMOSD

One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.

October 21st, 2026

NeuroVoices: Bruce Bebo, PhD, on Big Bets for Breakthroughs and the Campaign to End MS

The chief research and medical affairs officer at the National MS Society discussed AI-enabled imaging, biomarkers of progression, women's health across the lifespan, and the Society's Campaign to End MS.

October 20th, 2026

Decade of OPERA Data Supports Early Ocrelizumab Treatment Initiation in Relapsing Multiple Sclerosis

A newly published 10-year analysis of the OPERA I and II trials reported that starting ocrelizumab 2 years earlier was associated with less disability accrual in relapsing MS, with no new safety signals.

October 20th, 2026

Clene Submits NDA Seeking Accelerated Approval for ALS Drug

Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years of evolving FDA guidance.

October 20th, 2026

Amyloid Vaccine AV-1959R Generates Antibodies in All Phase 1 Recipients

In a 16-person placebo-controlled trial, every cognitively unimpaired adult given AV-1959R developed anti-amyloid-beta antibodies, while placebo recipients stayed at baseline.